chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sore arm at the injection site; Fatigue; Feel "funny"; Fever of 102 and next morning fever of 101; Severe shivering; This spontaneous case was reported by a nurse and describes the occurrence of FEELING ABNORMAL (Feel "funny"), VACCINATION SITE PAIN (Sore arm at the injection site), PYREXIA (Fever of 102 and next morning fever of 101), CHILLS (Severe shivering) and FATIGUE (Fatigue) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     Concurrent medical conditions included Anemia (thalessemia trait) since 10-Dec-1958, Palpitations since 02-Jun-1970 and Dry eyes since 14-Aug-2018. Concomitant products included ESTRADIOL (ESTROGEN) from 01-Jul-2015 to an unknown date, PROGESTERONE from 01-Jul-2015 to an unknown date and TESTOSTERONE from 01-Jul-2015 to an unknown date for Menopause, MULTI VITAMIN ONE A DAY and FISH OIL for an unknown indication.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced PYREXIA (Fever of 102 and next morning fever of 101) and CHILLS (Severe shivering). On 11-Jan-2021 at 10:00 PM, the patient experienced FEELING ABNORMAL (Feel "funny"). On 12-Jan-2021, the patient experienced VACCINATION SITE PAIN (Sore arm at the injection site) and FATIGUE (Fatigue). On 12-Jan-2021, FATIGUE (Fatigue) had resolved. At the time of the report, FEELING ABNORMAL (Feel "funny"), VACCINATION SITE PAIN (Sore arm at the injection site), PYREXIA (Fever of 102 and next morning fever of 101) and CHILLS (Severe shivering) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Jan-2021, Body temperature: 102 (High) 102. On 12-Jan-2021, Body temperature: 101 (High) 101.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient was on unspecified antibiotics before the first dose was administered.  Patient reports self-treating with acetaminophen.   This case was linked to MOD-2021-090019 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2021: Updated concomitant medications, updated event details
Vaccinated at about 9:50am Five minutes after vaccination, complained of itchy or "dry" throat. Gave water. 10 minutes after vaccination complained of throat beginning  to close up. 10:01am given 0.3mg Epinephrine into right thigh. 911 called. 10:03 given 25mg Diphenhydramine oral tablet. 10:06am pulse 90 BPM. 10:09 pulse 96 BPM. She started to feel better by the time EMS arrived.  10:16am EMS took her to Hospital.  She was returned home in the afternoon. Unknown if any further complications.
arm swollen; arm red; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING and ERYTHEMA in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced PERIPHERAL SWELLING and ERYTHEMA. At the time of the report, PERIPHERAL SWELLING and ERYTHEMA outcome was unknown. Not Provided.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.    This case was linked to US-MODERNATX, INC.-MOD-2021-121334 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 27-Apr-2021: Significant: 2nd dose information was provided. Sender's Comments:  US-MODERNATX, INC.-MOD-2021-121334: First dose case.
Received my vaccine on 12/04/2021 - Normal Symptoms 12-14hrs after shot. Body Chills with a very hot abdomen. Normal shot pain and discomfort in left arm. Itchy rash appeared about 6:30pm (12/06/2021) 2 days after shot on my right side abdomen. Rash continued to become worse. also started to get rash on right side of back. Went to my providers office 4 days after my shot (12/08/2021). I was diagnosed with having shingles. Started taking an antiviral medication. I also ended up having nerve pain for about 6-9 days. Shingles has healed. However I do have a light mark on my stomach were my shingles was.
DURING THE 15 MINUTE OBSERVATION PERIOD, ABOUT 5 TO 10 MINUTES POST VACCINE THE PT FAINTED WHILE SITTING IN HER CHAIR AND FELL OUT OF THE CHAIR. I INSTRUCTED A TECH TO 911 WHILE RAN TO THE PT. AS I TOUCHED HER TO FEEL FOR A PULSE SHE REGAINED CONSCIOUSNESS. I EXPLAINED WHAT HAPPENED AND ASKED HER TO STAY WHERE SHE WAS AT UNTIL PARAMEDICS CAME.  SHE WAS ALERT AND ABLE TO ANSWER QUESTIONS.  THE PARAMEDICS ARRIVED ABOUT 5 MINUTES LATER. THEY GOT HER UP AND SHE HAD A SEIZURE.  THE TOOK HER TO AND UNKNOW HOSPITAL
Administered first dose of Moderna vaccine today. Did not disclose receipt of J&J vaccine on 3/12/21. No adverse reactions at this time.
Big sacks underneath armpit, like fluid in the sack, it's skin but a sack underneath; Like you got fluid on the knee; Itches; Armpit was sore; Arms were sore; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (Arms were sore), MASS (Big sacks underneath armpit, like fluid in the sack, it's skin but a sack underneath), JOINT EFFUSION (Like you got fluid on the knee), PRURITUS (Itches) and AXILLARY PAIN (Armpit was sore) in a 57-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 013H22A) for COVID-19 prophylaxis.     Concurrent medical conditions included Cholesterol. Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR) for Cholesterol.    On 31-Oct-2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 01-Nov-2022, the patient experienced PAIN IN EXTREMITY (Arms were sore). On 02-Nov-2022, the patient experienced MASS (Big sacks underneath armpit, like fluid in the sack, it's skin but a sack underneath), JOINT EFFUSION (Like you got fluid on the knee), PRURITUS (Itches) and AXILLARY PAIN (Armpit was sore). At the time of the report, PAIN IN EXTREMITY (Arms were sore), MASS (Big sacks underneath armpit, like fluid in the sack, it's skin but a sack underneath), JOINT EFFUSION (Like you got fluid on the knee), PRURITUS (Itches) and AXILLARY PAIN (Armpit was sore) outcome was unknown.            Patient received first dose of Moderna COVID-19 Vaccine on 16-Apr-2021 (Batch number: 040B21A) and second dose of Moderna COVID-19 Vaccine on 14-May-2021 (Batch number: 022C21A).  Patient had not taken any medications following the vaccine.   This case was linked to US-MODERNATX, INC.-MOD-2022-668181 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-668181:Wife case :MOD22-028423
They inadvertently administered the 2nd booster dose to a couple who are less than 50 years old and who are not immunocompromised; This spontaneous case was reported by a nurse and describes the occurrence of EXTRA DOSE ADMINISTERED (They inadvertently administered the 2nd booster dose to a couple who are less than 50 years old and who are not immunocompromised) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 065A21A, 093A21A, 045B21A and 071F21A) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On 08-Apr-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXTRA DOSE ADMINISTERED (They inadvertently administered the 2nd booster dose to a couple who are less than 50 years old and who are not immunocompromised). At the time of the report, EXTRA DOSE ADMINISTERED (They inadvertently administered the 2nd booster dose to a couple who are less than 50 years old and who are not immunocompromised) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that patient was not immunocompromised. No concomitant drug was reported. The reporter stated that they started administering the second booster dose to patients in their facility. The patient received second booster dose on 8-Apr-2022. No treatment drug was reported.
increase in feelings of arthritis in our arthritic areas; night sweating; aching everywhere; Joint pain; Fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRITIS (increase in feelings of arthritis in our arthritic areas), NIGHT SWEATS (night sweating), MYALGIA (aching everywhere), ARTHRALGIA (Joint pain) and PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 07-Sep-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRITIS (increase in feelings of arthritis in our arthritic areas), NIGHT SWEATS (night sweating), MYALGIA (aching everywhere), ARTHRALGIA (Joint pain), PYREXIA (Fever) and CHILLS (chills). At the time of the report, ARTHRITIS (increase in feelings of arthritis in our arthritic areas), NIGHT SWEATS (night sweating), MYALGIA (aching everywhere), ARTHRALGIA (Joint pain), PYREXIA (Fever) and CHILLS (chills) outcome was unknown.            Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.    This case was linked to MOD-2021-317606, MOD-2021-312693, MOD-2021-316965.
Information has been received from a licensed practical nurse concerning a female with no pertinent medical history or drug reactions/allergies who on 04-SEP-2007 was vaccinated intramuscularly in the left arm with PNEUMOVAX 23 (0.5 ml) (lot # 657039/0698U) There was no concomitant medication. In September 2007 (exact onset date unknown), the patient's left arm became swollen from the shoulder to the elbow. The patient sought treatment at her physician's office on 06-SEP-2007. Conservative treatment with BENADRYL and ice failed and the patient was given an intramuscular injection of KENALOG and oral steroids in a dose pack. The patient fully recovered (date unspecified). Additional information has been requested.
received 3rd dose of Shingrix; received 1st dose 03/06/2018 2nd dose 05/04/2018; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 70-year-old female patient who received Herpes zoster (Shingrix) (batch number 7S3NF, expiry date 18th December 2022) and (batch number 3B55B, expiry date 18th December 2022) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 06th March 2018).   On 21st October 2021, the patient received the 3rd dose of Shingrix. On an unknown date, the dose was an unknown dose. On 4th May 2018, the patient received the 2nd dose of Shingrix. On 4th May 2018, not applicable after receiving Shingrix and unknown after receiving Shingrix, the patient experienced drug dose administration interval too short. On 21st October 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered and drug dose administration interval too short were unknown.  Additional details were provided as follows: The reporter called to report that a patient received shingrix 2nd dose 04th May 2018 and also received a 3rd dose of Shingrix, which led to drug dose administration interval too short and extra dose administered. The reporter stated that they want to have data on this. The reporter consented to follow up.
Fully vaccinated with two doses of Pfizer. Tested positive for COVID 19 on 02/05/2022. Admitted to Medical Center on 02/05/2022. Expired on 02/10/2022 while still hospitalized.
lymph nodes are enlarged on her neck and armpit area.; pain in the neck; This is a spontaneous report received from contactable reporter(s) (Other HCP and Consumer or other non HCP). The reporter is the patient.  A 45 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 09Aug2021 (Lot number: EW0169) at the age of 45 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Tachycardia" (unspecified if ongoing), notes: Verbatim: Tachycardia; "Insomnia" (unspecified if ongoing), notes: Verbatim: Insomnia; "Depression" (unspecified if ongoing), notes: Verbatim: Depression; "Obesity" (unspecified if ongoing), notes: Verbatim: Obesity; "Sleep" (unspecified if ongoing). Concomitant medication(s) included: AMITRIPTYLINE taken for sleep disorder; PROPRANOLOL taken for tachycardia. Past drug history included: Levaquin, reaction(s): "Allergic to Levaquin", notes: She is Allergic to Levaquin and Doxycycline.; Doxycycline, reaction(s): "Allergy: Doxycycline". The following information was reported: LYMPHADENOPATHY (non-serious) with onset 11Aug2021, outcome "recovered" (Aug2021), described as "lymph nodes are enlarged on her neck and armpit area."; NECK PAIN (non-serious) with onset 11Aug2021, outcome "recovered" (Aug2021), described as "pain in the neck". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient received first vaccination dose on 09Aug2021, after she has been having issues with lymph nodes. On the right side the lymph nodes are enlarged on patient neck and armpit area. Patient got an ultrasound done with labs. Patient's HCP still recommended to get the 2nd Pfizer vaccine. Enlarged Lymph nodes: It started about 2 days after the first dose, it started off with pain in the neck, patient did not have a sore throat but when moving the neck she could feel it pull, patient then physically felt the enlargement by feeling it with touch. It had subsided after a week and a half. Patient clarified that she was already prescribed amitriptyline prior to receiving the vaccines as needed for sleep. Patient was on propranolol twice a day for tachycardia. Reporter stated that patient has had a lot of lab work done starting on 18Aug2021.  No follow-up attempts are possible. No further information is expected.
Received 1st dose subcutaneously; This case was reported by a other health professional via interactive digital media and described the occurrence of intramuscular formulation administered by other route in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   In April 2022, the patient received the 1st dose of Shingrix (subcutaneous). In April 2022, unknown after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown.       Additional Information: GSK Receipt Date:  08-APR-2022 Reporter's Comments: The patient received 1st dose of shingrix subcutaneously. The reporter asked if the patient need another dose intramuscularly. The patient received 1st dose 2 days before day of reporting.   Additional Supportive Information: This case was reported by a other health professional via interactive digital media . The patient received shingrix subcutaneously which led to intramuscular formulation administered by other route.
Information has been received concerning a pt who on 12/01/97 was vaccinated with varicella vaccine. On 06/22/00, the pt developed chickenpox. The pt was covered with marks. The pt sought unspecified medical attention.
enlarged lymph node; developed a decent amount of pain under his left arm; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): 2022NVXUS000003536 (Novavax).  A 39-year-old male patient received BNT162b2 (BNT162B2), in Feb2021 as dose 2, single (Batch/Lot number: unknown) at the age of 38 years for covid-19 immunisation. The patient's family history included: "Heart disease" (unspecified if ongoing), notes: He had a history of heart disease in his family. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Single), administration date: Feb2021, when the patient was 38 years old, for COVID-19 immunization, reaction(s): "It was reported that after the 1st dose his arm hurt and he was tired.", "It was reported that after the 1st dose his arm hurt and he was tired.". The following information was reported: LYMPHADENOPATHY (non-serious), outcome "unknown", described as "enlarged lymph node"; AXILLARY PAIN (non-serious), outcome "unknown", described as "developed a decent amount of pain under his left arm". The events "enlarged lymph node" and "developed a decent amount of pain under his left arm" required physician office visit.  Additional information: On 16Sep2022, it was reported that a patient started treatment on Feb2021 with Pfizer BioNTech COVID-19 Vaccine of two doses for unspecified indication. It was reported that after the 1st dose his arm hurt and he was tired. After the 2nd dose, he developed a decent amount of pain under his left arm. He went to his doctor who said he had an enlarged lymph node. The pain was on and off and the same happened after the booster dose. It was concerning and he wanted to avoid it. He had a history of heart disease in his family. His doctor said getting the Novavax vaccine is a good idea.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Initial reaction:  night of April 1-2: moderate leg aches, restlessness, hip joint pain, feeling feverish w/out fever, mild chills April 2-3: moderate to severe fatigue, lethargy symptoms eased on evening of April 3 Secondary reaction: April 4, evening through today, April 7: lymph nodes in left armpit, left side of neck, left jaw sore and tender, possibly slightly swollen. Back left jaw felt slightly numb on first day. Left side of neck feels as if muscles sprained. No fever. Brief, mild tenderness at injection site on right arm.
Patient with 2 COVID vaccinations who admitted to hospital with complications from COVID.  Provider d/c note:  "Patient is a 62-year-old male with a past medical history of hypertension, hyperlipidemia who presents with shortness of breath.  Desaturates with ambulation and started on Decadron and remdesivir.  The next day patient did not desaturate with ambulation.  PT/OT evaluation recommended home independently/with assist and his sister can help if needed..  Echo shows normal ejection fraction.  Patient agreeable to leaving before remdesivir is completed, not indicated any ways without hypoxia.  He was discharged with Decadron to complete a 10 day course.  He was also given Mucinex, albuterol p.r.n.."
DIZZINESS; SEVERE HEADACHE; NAUSEA; TEMPERATURE OF 100; This spontaneous report received from a health care professional concerned an 18 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included covid-19. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 13:00 at right arm for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, Laboratory data included: SARS-CoV-2 PCR test (NR: not provided) POSITIVE. On APR-2021, the subject experienced dizziness. On APR-2021, the subject experienced severe headache. On APR-2021, the subject experienced nausea. On APR-2021, the subject experienced temperature of 100. Laboratory data included: Body temperature (NR: not provided) 100 F. On 07-APR-2021 05:30, treatment medications included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the severe headache, dizziness, nausea and temperature of 100 was not reported. This report was non-serious.
Elevated temp - dizziness, nauseated, H/A started day after injection and lasted 2 days.  No treatment necessary.
Diverticulitis flare up...treated with Flagyl and Cipro, amd getting better
Tingling in her arm, hands and legs; they thought it was maybe like a hit nerve when they gave me injection but since then it has all traveled down to my hands and legs; This is a spontaneous report from a Pfizer-sponsored program.  A contactable consumer (patient) reported for herself. A female patient of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration on 10Jun2021 (Batch/Lot Number: EW0180) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received the Pfizer COVID-19 Vaccine on 10Jun2021 and after receiving it she experiencing tingling in the arm. The symptoms did not go away when in the patient had to be referred to a neurologist and she still have the symptoms the tingling in her arm, hands and legs and also she is asking if there are any others who experienced the side effect. When paraphrased the concern, consumer stated, yes, thought it was maybe like a hit nerve when they gave me injection but since then it had all traveled down to my hands and legs and it had not just isolated to one arm it spread. When probed if it was the first vaccine, Consumer stated that the patient just had the first vaccine because as far as know it was the adverse reaction and so the patient was concerned with taking the second dose. The patient was still trying to remain a little bit anonymous until got more information to whether was this a normal reaction. Have you guys heard this before and typically how long does it take to go away, ight now, the patient was just trying to fish for some information because concern was whether to have the second vaccination especially with this not going away. Patient was informed about the Medical Information Department for the concern and was provided with the contact for Pfizer Medical Information as Option 3 and was informed that the department was open from Monday to Friday, from 8am to 8pm. Patient stated, If you do not mid transferring her, that would be great. The patient was unwilling to complete the report and requested for transfer. Call was disconnected and transfer was unsuccessful. Hence, limited information was available. The outcome of event was unknown.
After patient was watched for 15 mins she was discharge with her son. Just prior to leaving the building she became pale, nauseated and started dry heaving. VS remained stable although she appeared tired. 20mg of pepcid given by mouth, 50mg of benadryl and 125mg of solumedrol given IM. Patient was then transferred to the ED via wheel chair for further monitoring and evaluation.